The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer

Highlights • A low, non-cytotoxic concentration of cisplatin is utilised. • We elucidate the role of mTOR in response to cisplatin and combination treatments • Cytotoxicity of cisplatin is greatly enhanced when mTOR is inhibited.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Toxicology (Amsterdam) 2015-09, Vol.335, p.72-78
Hauptverfasser:	Leisching, G.R, Loos, B, Botha, M.H, Engelbrecht, A.-M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Antineoplastic Agents - toxicity Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis Apoptosis - drug effects Autophagy - drug effects Cancer Cell Cycle - drug effects Cervical cancer Chemotherapy Cisplatin Cisplatin - pharmacology Cisplatin - toxicity Dose-Response Relationship, Drug Emergency Female Gene Expression Regulation, Neoplastic HeLa Cells Humans In vitro testing Inhibition Low concentrations Medical services mTOR Pathways Protein Kinase Inhibitors - pharmacology Proteins RNA Interference Signal Transduction - drug effects Sirolimus - pharmacology Squamous Intraepithelial Lesions of the Cervix - enzymology Squamous Intraepithelial Lesions of the Cervix - genetics Squamous Intraepithelial Lesions of the Cervix - pathology TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - genetics TOR Serine-Threonine Kinases - metabolism Transfection Uterine Cervical Neoplasms - enzymology Uterine Cervical Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • A low, non-cytotoxic concentration of cisplatin is utilised. • We elucidate the role of mTOR in response to cisplatin and combination treatments • Cytotoxicity of cisplatin is greatly enhanced when mTOR is inhibited.
ISSN:	0300-483X 1879-3185
DOI:	10.1016/j.tox.2015.07.010